USP9x transcript levels were significantly lower in several cancers compared with normal controls, including breast, thyroid, prostate, liver hepatocellular carcinoma, kidney papillary and ccRCC (Figure 5a). Here, USP9X is linked to nonpapillary renal cell carcinoma.